The Economic Times
English EditionEnglish Editionहिन्दी
| E-Paper
Search
+

    Pause and Proceed: More downs than ups in this week's search for Covid-19 vaccine

    , ET Bureau|
    Johnson & Johnson pauses trial
    1/5

    Johnson & Johnson pauses trial

    In the third leg of its vaccine trial, Johnson and Johnson said it was halting the trial after one of the participants developed an unknown illness. The company said such pauses are not uncommon in clinical trials, and the number of serious adverse events (SAE) can reasonably be expected to increase in trials involving a large number of participants. Further, as many trials are placebo-controlled, it is not always immediately apparent whether a participant received a placebo.

    AP
    Remdesivir does not reduce mortality
    2/5

    Remdesivir does not reduce mortality

    One of the most awaited results from the WHO’s Solidarity Trials came on Friday, shooting down the most famous drug of the pandemic — Remdesivir. US drugmaker Gilead’s experimental drug had little or no effect on 28-day mortality (deaths within 28 days of being diagnosed with a disease). This was one of the largest trials in the world spanning across 30 countries.

    AP
    Pfizer to seek approval in November
    3/5

    Pfizer to seek approval in November

    Vaccine approval has become one of the most pressing political issues of the pandemic, especially in the US. Pfi zer, one of the front runners that was not asked to submit its vaccine for approval before the US elections, said it will apply for an emergency approval in the third week of November. Pfi zer said its data would be reviewed not only by FDA scientists but also by an external panel of independent experts at a publicly held meeting convened by the agency.

    AP
    Serum Institute applies for change in trial protocol
    4/5

    Serum Institute applies for change in trial protocol

    The trial design of the muchawaited vaccine that the Serum Institute of India is developing on its own will undergo some changes as the company now wants to expand the number and profi le of its participants. SII’s application has to be cleared by the Drug Controller General of India and this could delay the process.

    AP
    Hindustan Syringes sends first consignment to Covax
    5/5

    Hindustan Syringes sends first consignment to Covax

    The WHO initiative of pooling resources for equitable distribution of Covid vaccines is taking off. India’s Hindustan Syringes, which sent the fi rst shipment of 56 m syringes to the Covax facility this week, will scale up production to a billion in H12021, the company said.

    Reuters
    The Economic Times
    X
    User